49 Results for "

MTOR complex

" in MedChemExpress (MCE) Product Catalog:
Products (49)

49 Results for "MTOR complex" in MCE Product Catalog:

139
139 Publications Verification
Cat. No.: HY-13003
CAS No.: 1222998-36-8
Purity:  99.28%
Target:  

mTOR Autophagy

Research Areas:  

Cancer

Torin 1 is a potent inhibitor of mTOR with an IC50 of 3 nM. Torin 1 inhibits both mTORC1/2 complexes with IC50 values between 2 and 10 nM. Torin 1 is an effective inducer of autophagy.
loading...
    loading...
119
119 Cited Publications
Cat. No.: HY-10218
CAS No.: 159351-69-6
Purity:  99.85%
Synonyms: RAD001; SDZ-RAD
Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective, orally active, blood-brain barrier-permeable mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .
loading...
    loading...
31
31 Cited Publications
Cat. No.: HY-15247
CAS No.: 1009298-59-2
Purity:  99.32%
Synonyms: AZD2014
Target:  

mTOR Autophagy Apoptosis

Research Areas:  

Cancer

Vistusertib (AZD2014) is an ATP competitive mTOR inhibitor with an IC50 of 2.81 nM. AZD2014 inhibits both mTORC1 and mTORC2 complexes.
loading...
    loading...
26
26 Cited Publications
Cat. No.: HY-N0112
CAS No.: 27200-12-0
Synonyms: Ampelopsin; Ampeloptin
Dihydromyricetin is a potent inhibitor with an IC50 of 48 μM on dihydropyrimidinase. Dihydromyricetin can activate autophagy through inhibiting mTOR signaling. Dihydromyricetin suppresses the formation of mTOR complexes (mTORC1/2). Dihydromyricetin is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC50 of 22 μM.
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-50710
CAS No.: 938440-64-3
Target:  

mTOR

Research Areas:  

Cancer

KU-0063794 is a potent and specific mTOR inhibitor, inhibiting both the mTORC1 and mTORC2 complexes with IC50s of 10 nM.
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-16397A
CAS No.: 834-28-6
Synonyms: Phenethylbiguanide hydrochloride
Phenformin (Phenethylbiguanide) hydrochloride is an orally active biguanide hypoglycemic agent. Phenformin hydrochloride inhibits mitochondrial respiratory chain complex I, leading to an increased AMP/ATP ratio, activation of AMPK, and subsequent inhibition of the mTOR pathway, thereby suppressing cell proliferation, inducing apoptosis and autophagy. Phenformin hydrochloride inhibits cancer stem cells (CSCs) and possesses potent antitumor potential .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-16397
CAS No.: 114-86-3
Synonyms: Phenethylbiguanide
Phenformin (Phenethylbiguanide) is an orally active biguanide hypoglycemic agent. Phenformin inhibits mitochondrial respiratory chain complex I, leading to an increased AMP/ATP ratio, activation of AMPK, and subsequent inhibition of the mTOR pathway, thereby suppressing cell proliferation, inducing apoptosis and autophagy. Phenformin inhibits cancer stem cells (CSCs) and possesses potent antitumor potential .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-10681
CAS No.: 1197160-78-3
Purity:  99.68%
Synonyms: PKI-587; PF-05212384
Target:  

PI3K mTOR

Research Areas:  

Cancer

Gedatolisib (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and mTOR with IC50s of 0.4 nM, 5.4 nM and 1.6 nM, respectively . Gedatolisib is equally effective in both complexes of mTOR, mTORC1 and mTORC2 .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-15272
CAS No.: 1062159-35-6
Purity:  99.75%
Target:  

mTOR

Research Areas:  

Inflammation/Immunology Cancer

WAY-600 is a potent, ATP-competitive, and selective mTOR inhibitor with an IC50 of 9 nM for recombinant mTOR enzyme. WAY-600 blocks mTOR complex 1/2 (mTORC1/2) assemble and activation.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-100222
CAS No.: 1429639-50-8
Purity:  98.39%
Target:  

mTOR

Research Areas:  

Cancer

CZ415 is a potent and highly selective mTOR inhibitor with a pIC50 of 8.07. CZ415 inhibits mTORC1 and mTORC2 protein complex.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-137978A
CAS No.: 1914148-73-4
Purity:  99.29%
Synonyms: GNS561 hydrochloride
Ezurpimtrostat hydrochloride (GNS561 hydrochloride) is an orally active PPT1 inhibitor, autophagy inhibitor, immunomodulator, anti-inflammatory agent, and anticancer agent. Ezurpimtrostat hydrochloride inhibits PPT1, dysregulates lysosomal function, redistributes mTOR, and induces apoptosis. Ezurpimtrostat hydrochloride reduces IFN‑α, CRP, immune complex deposition, and SARS‑CoV‑2 viral load. Ezurpimtrostat hydrochloride can be used for the study of systemic lupus erythematosus, SARS‑CoV‑2, hepatocellular carcinoma, fibrosis, and related disorders .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-137978
CAS No.: 1914148-72-3
Synonyms: GNS561
Ezurpimtrostat (GNS561) is an orally active PPT1 inhibitor, autophagy inhibitor, immunomodulator, anti-inflammatory agent, and anticancer agent. Ezurpimtrostat inhibits PPT1, dysregulates lysosomal function, redistributes mTOR, and induces apoptosis. Ezurpimtrostat reduces IFN‑α, CRP, immune complex deposition, and SARS‑CoV‑2 viral load. Ezurpimtrostat can be used for the study of systemic lupus erythematosus, SARS‑CoV‑2, hepatocellular carcinoma, fibrosis, and related disorders .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-15248
CAS No.: 1207360-89-1
Purity:  98.02%
Target:  

mTOR Autophagy

Research Areas:  

Cancer

GDC-0349 is a potent and selective ATP-competitive mTOR inhibitor with a Ki of 3.8 nM. GDC-0349 inhibits of both mTORC1 and mTORC2 complexes.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P80837
Synonyms: MTOR; FRAP; FRAP1; FRAP2; RAFT1; RAPT1; Serine/threonine-protein kinase MTOR; FK506-binding protein 12-rapamycin complex-associated protein 1; FKBP12-rapamycin complex-associated protein; Mammalian target of rapamycin; MTOR; Mechanistic tar

Host:  

Rabbit

Application:  

WB, IHC-P

Reactivity:  

Human, Mouse

loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-136265
CAS No.: 695207-56-8
Purity:  99.20%
Research Areas:  

Cancer

BC-LI-0186 is a potent and selective inhibitor of Leucyl-tRNA synthetase (LRS; LeuRS) and Ras-related GTP-binding protein D (RagD) interaction (IC50=46.11 nM). BC-LI-0186 competitively binds to the RagD interacting site of LRS (Kd=42.1 nM) and has on effects on LRS-Vps34, LRS-EPRS, RagB-RagD association, mTORC1 complex formation or the activities of 12 kinases. BC-LI-0186 can effectively suppress the activity of cancer-associated?MTOR?mutants and the growth of rapamycin-resistant cancer cells.?BC-LI-0186 is a promising agent for lung cancer research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-124582
CAS No.: 1361198-80-2
Purity:  ≥98.0%
Target:  

Autophagy mTOR

Research Areas:  

Cancer

NEO214 is an autophagy inhibitor and a covalent conjugate of the PDE4 inhibitor Rolipram (HY-16900) and perillyl alcohol (HY-N7000). It has anti-cancer activity and blood-brain barrier (BBB) permeability. Over sex. NEO214 prevents autophagy-lysosome fusion, thereby blocking autophagic flux and triggering glioma cell death. The process involves mTOR activation, andTFEB(Transcription Factor EB) aggregation. NEO214 inhibitionMacroautophagy/autophagy in glioblastoma cells has the potential to overcome chemotherapy resistance in glioblastoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P80759
Synonyms: MTOR; FRAP; FRAP1; FRAP2; RAFT1; RAPT1; Serine/threonine-protein kinase MTOR; FK506-binding protein 12-rapamycin complex-associated protein 1; FKBP12-rapamycin complex-associated protein; Mammalian target of rapamycin; MTOR; Mechanistic tar

Host:  

Rabbit

Application:  

WB, IHC-P, ICC/IF, IP, FC

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
Cat. No.: HY-134508
CAS No.: 34435-05-7
Purity:  99.92%
C24-Ceramide is an orally active competitive binding agonist of PIP4K2C (mTOR complex regulator), thereby activating the mTOR signaling pathway. At the same time, C24-Ceramide changes the membrane morphology by inducing the formation of a partially interlocked gel phase in the phospholipid bilayer. C24-Ceramide can promote the proliferation and migration of keratinocytes to accelerate skin wound healing and drive the proliferation and metastasis of gallbladder cancer cells. The level of C24-Ceramide in serum can be used as a diagnostic marker for gallbladder cancer .
loading...
    loading...
Cat. No.: HY-175751
CAS No.: 3063346-83-5
Target:  

mTOR

Research Areas:  

Cancer

LRK-4189 is an orally active PIP4K2C (a regulator of mTOR complex) degrader and type 1 immune activator. LRK-4189 induces the degradation of the lipid kinase PIP4K2C. LRK-4189 triggers the interferon signaling pathway in microsatellite-stable (MSS) colorectal cancer cells, activates immunogenic tumor killing, and induces endogenous cell death. LRK-4189 sensitizes microsatellite-stable colorectal cancer tumors to NK cell killing and dendritic cell phagocytosis. LRK-4189 can be used for the research of microsatellite-stable colorectal cancer .
loading...
    loading...
Cat. No.: HY-10218S
CAS No.: 1338452-54-2
Purity:  98.74%
Synonyms: RAD001-d4; SDZ-RAD-d4
Everolimus-d4 is the deuterium labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .
loading...
    loading...